Marie Thibault
Stock Analyst at BTIG
(3.90)
# 3,728
Out of 4,874 analysts
72
Total ratings
52.94%
Success rate
9.82%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.98 | +302.68% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $9.28 | +180.17% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $309.83 | -12.86% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $166.71 | +1.97% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $40.84 | +59.16% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $104.58 | -11.07% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $74.77 | +49.79% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $32.88 | +61.19% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $85.04 | +41.11% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.16 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.20 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $14.05 | +42.35% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $152.69 | -8.31% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.86 | -22.28% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $133.67 | -6.49% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.32 | +430.30% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.40 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.50 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $208.99 | -97.13% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.98
Upside: +302.68%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $9.28
Upside: +180.17%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $309.83
Upside: -12.86%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $166.71
Upside: +1.97%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $40.84
Upside: +59.16%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $104.58
Upside: -11.07%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $74.77
Upside: +49.79%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $32.88
Upside: +61.19%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $85.04
Upside: +41.11%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.16
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.20
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $14.05
Upside: +42.35%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $152.69
Upside: -8.31%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $3.86
Upside: -22.28%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $133.67
Upside: -6.49%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.32
Upside: +430.30%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.40
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.50
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $208.99
Upside: -97.13%